Intramuscular vaccine adjuvants are compounds that are added to vaccine formulations to enhance immune responses to vaccine antigens and provide longer lasting immunity. Some key advantages include increasing the efficacy of vaccines by eliciting a more robust immune response through increased antibody production and longer duration of immunity with lower antigen load. This enables vaccine manufacturers to reduce production costs and ensure adequate supply of vaccines across the world.
Intramuscular vaccine adjuvants are compounds added to vaccine formulations to enhance immune responses to vaccine antigens and provide longer lasting immunity with a single vaccination. Aluminum salts are commonly used adjuvants in licensed vaccines, however novel adjuvants such as saponin-based adjuvants, oil-in-water emulsions, liposomes and pathogen-associated molecular patterns show improved immune responses.
The global Intramuscular Vaccine Adjuvants Market is estimated to be valued at US$ 694.19 Mn in 2023 and is expected to exhibit a CAGR of 6.7% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the key trends in the global intramuscular vaccine adjuvants market is the increasing adoption of aluminum-free novel adjuvants. Traditional aluminum adjuvants are associated with reactogenicity at the injection site and may contribute to vaccine hesitancy. This has driven research on alternative adjuvants that elicit prolonged, enhanced immunity comparable or superior to aluminum with improved safety profiles. Oil-in-water emulsions such as MF59, AF03, and AS01; saponin-based adjuvants such as QS-21; and pathogen recognition receptor agonists such as MPL are novel categories of adjuvants replacing traditional aluminum salts in development pipelines and commercialized vaccines.Furthermore, advances in immunology have enabled rational design and production of synthetic adjuvants as defined molecular structures aimed at stimulating specific arms of the immune system.
Segment Analysis
Intramular Vaccine Adjuvant market is segmented on the basis of product, route of administration and application. By product, the market is dominated by particulate adjuvants sub-segment owing to its ability to induce strong immune responses such as activation of phagocytes, secretion of chemokines and cytokines and activation and maturation of dendritic cells. By route of administration, intramuscular segment holds the largest share due to high preference of intramuscular route of vaccine administration. By application, infectious disease segment dominates the market as majority of vaccines available in the market are for infectious diseases like influenza, hepatitis, meningitis etc.
Key Takeaways
The Global Intramuscular Vaccine Adjuvants Market Demand is expected to witness high growth, exhibiting CAGR of 6.7% over the forecast period, due to increasing prevalence of infectious diseases worldwide.
Regional analysis - North America region holds the largest share in global Intramuscular Vaccine Adjuvants market due to increasing R&D activities for vaccine development & presence of key players in the region. Asia Pacific region is expected to witness fastest growth rate owing to high patient population and rising government funding for healthcare.
Key players operating in the Intramuscular Vaccine Adjuvants market are Novavax, Inc., Adjuvance Technologies, Inc., Invivogen, Vaxine Pty Ltd., SEPPIC, SPI Pharma, Inc., Agenus Inc., Avanti Polar Lipids, Inc., CSL Limited, OZ Biosciences. Key players are focusing on new product launches and geographical expansion to strengthen their market presence.
Explorer more information on this topic, Please visit -
